Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 15.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.240. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of recent research reports. StockNews.com cut Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Sanford C. Bernstein assumed coverage on Biogen in a research report on Tuesday. They issued a “market perform” rating and a $160.00 price objective on the stock. Robert W. Baird increased their price objective on Biogen from $294.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Truist Financial decreased their price objective on Biogen from $302.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Citigroup decreased their price objective on Biogen from $190.00 to $160.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Seventeen equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $221.65.

Biogen Trading Down 5.1 %

BIIB stock traded down $7.13 during midday trading on Wednesday, hitting $132.27. 1,511,555 shares of the company’s stock were exchanged, compared to its average volume of 1,301,840. The stock’s fifty day moving average price is $148.28 and its 200-day moving average price is $174.33. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The company has a market cap of $19.27 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. Biogen has a one year low of $128.51 and a one year high of $238.00.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%. Research analysts predict that Biogen will post 16.42 earnings per share for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.